- prior evidence for SARS- CoV, MERS-CoV and influenza have shown that convalescent plasma transfusion is effective against infectious diseases
- multiple researches has shown that NAbs are robust as a therapeutic potential against COVID-19
- NAb CB6 has demonstrated strong viral inhibition in nonhuman primates
- cocktail antibodies have been suggested as more efficient

Northwestern University

State University of New York at Stony Brook

-  Support for the use of SARS-CoV-2 Ab for therapies
-  Evidence suggesting SARS-CoV-2 Ab may not be the most viable solution

SARS-CoV-2 Antibodies and their uses in future SARS-CoV-2 Therapies

Huang, Y., Sun, H., Yu, H., Li, S., Zheng, Q., & Xia, N. (2020). Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. Antibody Therapeutics, 3(4), 285-299.
https://doi.org/10.1093/abt/tbaa028

Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective 

Support for the use of SARS-CoV-2 Ab for therapies

- According to a Wuhan MedRxiv article, SARS-CoV-2 antibodies do not last long enough to make herd immunity or vaccines a likely solution. Additionally, SARS-CoV Ab therapies may not be applicable to SARS-CoV-2
-  antibody dependent enhancement (ADE) is of concern as a recent study on NAbs against MERS-CoV RBD has shown ADE
- some SARS-CoV-2 S mutations may be resistant to RBD-targeting NAbs (E484, F490, Q493, and S494)

Learn Before

Related